代谢药物初创公司Verdiva推出4.1亿美元和每周口服GLP-1药物-动脉网

Metabolic Meds Startup Verdiva Launches With $410M and a Weekly Oral GLP-1 Drug

MedCity News 等信源发布 2025-01-10 03:11



可切换为仅中文







GLP-1 drugs currently available for weight loss are administered as once-weekly injections. Verdiva Bio also aims to bring to patients once-a-week dosing, but in a more convenient pill. That would also give the startup’s drug a dosing edge over many of the potential next-generation metabolic medications in development as once-daily pills.

目前可用于减肥的GLP-1药物每周注射一次。Verdiva Bio还旨在为患者提供一周一次的剂量，但使用更方便的药丸。。

On Thursday, the startup .

。

revealed $410 million

透露4.1亿美元

to support its plans.

支持其计划。

The Verdiva drug, VRB-101, is part of a portfolio of experimental medicines acquired from China-based Sciwind Biosciences last year. Verdiva, which is based in London and has additional operations in San Francisco, holds global rights to these drugs outside of greater China and South Korea. According to Verdiva, these drugs are made with a proprietary oral delivery technology designed to enable oral dosing..

Verdiva药物VRB-101是去年从中国Sciwind Biosciences收购的实验药物组合的一部分。Verdiva总部位于伦敦，在旧金山有其他业务，在大中华区和韩国以外拥有这些药物的全球权利。据Verdiva称，这些药物采用专有的口服给药技术制成，旨在实现口服给药。。

Verdiva said a Phase 1 study conducted in Australia confirmed the viability of once-weekly dosing of VRB-101. No weight-loss figures were disclosed for this clinical trial. The company said this program is now ready to enter Phase 2 testing.

Verdiva说，在澳大利亚进行的一项第一阶段研究证实了每周服用一次VRB-101的可行性。该临床试验未披露体重减轻数字。该公司表示，该项目现已准备好进入第二阶段测试。

Health IT

健康IT

Reducing Clinical and Staff Burnout with AI Automation

利用人工智能自动化减少临床和员工的职业倦怠

As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.

随着技术的进步，人工智能工具将越来越多地减轻医疗保健提供者的管理负担。

By Dr. Michael Blackman, Chief Medical Officer at Greenway Health

由Dr。Greenway Health首席医疗官迈克尔·布莱克曼（MichaelBlackman）

“Our most mature program has the potential to be a first-in-class, once-weekly oral treatment for obesity and weight loss maintenance that could dramatically improve patient access and affordability,” Verdiva co-founder and CEO Khurem Farooq said in a prepared statement.

Verdiva联合创始人兼首席执行官Khurem Farooq在一份准备好的声明中表示：“我们最成熟的项目有可能成为一流的每周一次的肥胖和减肥维持口服治疗，可以显着改善患者的获取和负担能力。”。

The Verdiva pipeline also includes a once-weekly oral drug designed to target and activate amylin. The company said this drug could be used as a monotherapy or in combination with an oral GLP-1 agonist. The third program is a subcutaneously injected amylin agonist designed to be long-acting. Verdiva said this drug could be also be used as a monotherapy or in combination with a proprietary GLP-1 peptide drug..

Verdiva管道还包括每周一次的口服药物，旨在靶向和激活胰淀素。该公司表示，这种药物可以作为单一疗法或与口服GLP-1激动剂联合使用。第三个程序是皮下注射的胰淀素激动剂，旨在长效。Verdiva说，这种药物也可以作为单一疗法或与专有的GLP-1肽药物联合使用。。

Other companies are also developing amylin-targeting drugs.

其他公司也在开发针对胰淀素的药物。

Novo Nordisk’s amycretin targets both amylin and GLP-1

诺和诺德的胰淀素同时靶向胰淀素和GLP-1

. Viking Therapeutics, whose pipeline includes

.Viking Therapeutics，其管道包括

both injectable and oral agonists of GLP-1

GLP-1的注射和口服激动剂

, has another program that targets the amylin and calcitonin receptors.

，还有另一个针对胰淀素和降钙素受体的程序。

Verdiva’s Series A round was co-led by Forbion and General Atlantic. Other participants in the financing include RA Capital Management, OrbiMed, Logos Capital, Lilly Asia Ventures, and LYFE Capital.

Verdiva的A轮系列赛由Forbion和General Atlantic联合领导。其他融资参与者包括RA Capital Management、OrbiMed、Logos Capital、Lilly Asia Ventures和LYFE Capital。

presented by

提交人

Market Trends to Watch for Health Systems and Their Specialty Pharmacies

关注卫生系统及其专业药房的市场趋势

The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.

综合专科药房模式的未来前景光明-对于卫生系统，提供者，最重要的是，对于患者。

By Jake Gaffey, MBA, Chief Strategy Officer at Shields Health Solutions

作者：Jake Gaffey，MBA，Shields Health Solutions首席战略官

Photo: Peter Dazeley, Getty Images

照片：彼得·达泽利，盖蒂图片社

Topics